WASHINGTON DC (STL.News) – The Securities and Exchange Commission (SEC) yesterday filed an amended complaint naming Swiss resident Roland M. Mathys as a defendant in an insider trading case the SEC brought last year alleging that certain unknown traders made approximately $5 million in profits by making timely purchases of Bioverativ, Inc. call options in advance of the January 22, 2018 announcement that Sanofi S.A. would acquire Bioverativ.
The U.S. Attorney’s Office for the Southern District of New York announced parallel criminal charges against Mathys stemming from the same conduct.
The SEC’s amended complaint alleges that Mathys received material non-public information about Sanofi’s impending acquisition of Bioverativ from a Sanofi insider’s son. According to the amended complaint, Mathys used the information to purchase approximately $169,000 of out-of-the-money Bioverativ call options in the 10 days immediately leading up to the public announcement. The SEC alleges that Mathys’ purchases made up a significant portion of all reported options trades in the series of Bioverativ options he traded, including almost 100 percent of the market in several instances. By allegedly purchasing these options based on material non-public information, Mathys was able to turn his approximately $169,000 investment into profits of approximately $5 million. All or substantially all of these funds have been frozen in the United States or Switzerland.
The amended complaint charges Mathys with violating Section 14(e) of the Securities Exchange Act of 1934 and Rule 14e-3 thereunder. The Commission is seeking a permanent injunction, disgorgement of illegal trading profits plus prejudgment interest, and civil penalties.
Litigation Release No. 24500 – Securities and Exchange Commission v. Roland M. Mathys – No. 18-civ-00701-JGK (S.D.N.Y.)